Please login to the form below

Not currently logged in
Email:
Password:

Idera Pharmaceuticals names new CEO

Vincent Milano was most recently CEO of Viropharma

Vincent Milano has been appointed CEO of Idera Pharmaceuticals almost one year after stepping down as CEO of ViroPharma.

Milano left rare disease specialist ViroPharma in January 2014 shortly after the company was acquired by Shire Pharmaceuticals.

He now takes charge of Idera, a clinical-stage biopharmaceutical company that also has an interest in rare diseases.

Jim Geraghty, chairman of Idera, commented on Milano's success at ViroPharma: “Vin is an experienced biopharmaceutical executive with a proven track record of value creation, who led ViroPharma to become a widely admired company successfully delivering innovative treatments to patients with serious unmet medical needs."

Milano succeeds Sudhir Agrawal, who will remain at Idera as president of research and will serve on the company's board of directors.

“As a co-founding scientist and a pioneer in the field of nucleic acid therapeutics, he will continue to lead scientific research for the company,” said Geraghty.

Milano spent nearly 20 years at ViroPharma serving as chief financial officer from 1997 to 2006 when he was named CEO. His previous experience includes a senior manager role at accounting firm KPMG.

5th December 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....